Fig. 6.
Alas1-siRNA1 administration does not alter hepatic heme status or CYP2E1 activity. AIP mice were administered a single 1.0 mg/kg i.v. dose of Alas1-siRNA1 or Luc-siRNA, and the livers were isolated ∼24 h later to assess (A) heme saturation of TDO and (B) CYP2E1 activity. Data are shown as mean ± SD (n = 4–6). *P < 0.01, ANOVA.